Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/31/2012

SAN DIEGO, May 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Reports First Quarter 2012 Financial Results
2. Halozyme to Host First Quarter 2012 Financial Results Conference Call
3. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
4. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
5. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
6. Halozyme Announces Proposed Public Offering of Common Stock
7. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Dec. 9, 2016  Axovant Sciences Ltd. (NYSE: ... company focused on the treatment of dementia, today ... a Phase 2b trial evaluating treatment with intepirdine ... with donepezil plus placebo in people with mild-to-moderate ... of intepirdine to treatment was associated with reduced ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
(Date:12/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized by the ... National Standard. To learn more about Diplomat,s career opportunities, ... ... ... WorkplaceDynamics, LLC, a research firm specializing in organizational health and workplace ...
Breaking Medicine Technology:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... Mediaplanet ... awareness for organ transplantation while encouraging readers to sign up as an organ donor ... lifesaving organ transplant. , An organ donor can save up to 8 saves ...
(Date:12/8/2016)... Charleston, WV (PRWEB) , ... December 08, 2016 ... ... that it will become Quality Insights beginning January 1, 2017. The name ... emphasizes its commitment to measuring and improving health care quality. , “We are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... County, a Property owned by an affiliate of Seavest, has won a prestigious ... Medicine Southern Chester County ambulatory care center (ACC) was named “Best New Development, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
Breaking Medicine News(10 mins):